Thomas Jenuwein

Quick Facts

Full Name	Thomas Jenuwein
Occupation	Scientist
Date Of Birth	Dec 10, 1956(1956-12-10)
Age	68
Birthplace	Lohr am Main
Country	Germany
Birth City	Bavaria
Horoscope	Sagittarius

Thomas Jenuwein Biography

Thomas Jenuwein is one of the most popular and richest Scientist who was born on December 10, 1956 in Lohr am Main, Bavaria, Germany.

Thomas Jenuwein received his Ph.D. in molecular biology in 1987 from the EMBL, working on fos oncogenes in the laboratory of Rolf Müller and the University of Heidelberg and performed postdoctoral studies (1987-1993) on the immunoglobulin heavy chain (IgH) enhancer with Rudolf Grosschedl at the University of California San Francisco (UCSF). As an independent group leader (1993-2002) and then as a senior scientist (2002-2008) at the Research Institute of Molecular Pathology (IMP) in Vienna, he focused his research to chromatin regulation. Through this work, he and his team discovered the first histone lysine methyltransferase (KMT) that was published in 2000. He is currently director at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany where he heads the Department of Epigenetics. From 2004 to 2009, he coordinated the EU-funded network of excellence ‘The Epigenome’ , which connected more than 80 laboratories in Europe. Jenuwein is also co-editor of the first textbook on ‘Epigenetics’ that was published by Cold Spring Harbor Laboratory Press in 2007 and 2015. He is an ambassador for the dissemination of Science and is actively engaged with public lectures and radio and TV documentations to inform lay audiences about ‘Epigenetics’.

Chromatin is the physiological template of our genetic information, the DNA double helix. The basic subunits of chromatin, the histone proteins, function in the packaging of the DNA double helix and in controlling gene expression through a variety of histone modifications. When Jenuwein started his chromatin work in late 1993, no enzymes for histone modifications were known. He and his team cloned and characterized mammalian orthologs of dominant Drosophila PEV modifier factors containing the evolutionarily conserved SET domain, originally identified by the laboratory of Gunter Reuter. The SET domain is present in Su(var)3–9, Enhancer of zeste and Trithorax proteins, all of which had been implicated in epigenetic regulation without evidence of enzymatic activity. Overexpression of human SUV39H1 modulated the distribution of histone H3 phosphorylation during the cell cycle in a SET domain dependent manner. This insight, together with refined bioinformatic interrogation revealing a distant relationship of the SET domain with plant methyltransferases, suggested the critical experiment: to test recombinant SUV39H1 for KMT activity on histone substrates. This experiment revealed robust catalytic activity of the SET domain of recombinant SUV39H1 to methylate histone H3 in vitro and was shown to be selective for the histone H3 lysine 9 position (H3K9me3). This seminal discovery identified the first histone lysine methyltransferase for eukaryotic chromatin. An important follow-up discovery was to show that SUV39H1-mediated H3K9 methylation generates a binding site for the chromodomain of heterochromatin protein 1 (HP1). Together, these landmark findings established a biochemical pathway for the definition of heterochromatin and characterized Suv39h-dependent H3K9me3 as a central epigenetic modification for the repression of transcriptional activity. The in vivo function of the Suv39h KMT was demonstrated by the analysis of Suv39h double-null mice, which display chromosome segregation defects and develop leukemia. Together with Boehringer Ingelheim, he identified the first small molecule inhibitor for KMT enzymes via screening of a chemical library. During the following years, Jenuwein then addressed the function of heterochromatin towards transcriptional regulation and genomic organization, with a particular focus on the analysis of the non-coding genome. An initial map of the mouse epigenome was established by a cluster analysis of repressive histone modifications across repeat sequences and provided an important framework well ahead of the deep-sequencing advances in the profiling of epigenomes. Genome-wide maps for Suv39h-dependent H3K9me3 marks and Hiseq RNA sequencing revealed a novel role for the Suv39h KMT in the silencing of repeat elements (e.g. LINE and ERV retrotransposons) in mouse embryonic stem cells. The demonstration that the pericentric major satellite repeats have embedded transcription factor (TF) binding sites that are relevant for TF-mediated recruitment of Suv39h enzymes has provided a general targeting mechanism for the formation of heterochromatin. Most recent work has identified that repeat RNA transcripts from the major satellite repeats largely remain chromatin associated and form an RNA-nucleosome scaffold that is supported by RNA:DNA hybrids.

Thomas Jenuwein Net Worth

Thomas Jenuwein is one of the richest Scientist from Germany. According to our analysis, Wikipedia, Forbes & Business Insider, Thomas Jenuwein 's net worth $5 Million. (Last Update: December 11, 2023)

Thomas Jenuwein (born 1956) is a German scientist working in the fields of epigenetics, chromatin biology, gene regulation and genome function.

Height, Weight & Body Measurements

Thomas Jenuwein height Not available right now. Lamart weight Not Known & body measurements will update soon.

Who is Thomas Jenuwein Dating?

According to our records, Thomas Jenuwein is possibily single & has not been previously engaged. As of December 1, 2023, Thomas Jenuwein’s is not dating anyone.

Relationships Record : We have no records of past relationships for Thomas Jenuwein. You may help us to build the dating records for Thomas Jenuwein!

Facts & Trivia

Lamart Ranked on the list of most popular Scientist. Also ranked in the elit list of famous people born in Germany. Thomas Jenuwein celebrates birthday on December 10 of every year.

Top Facts about Thomas Jenuwein

1. Thomas Jenuwein is a German molecular biologist.
2. He was born on May 28, 1962 in Stuttgart, Germany.
3. Jenuwein is known for his research on epigenetics and chromatin biology.
4. He received his PhD from the University of Munich in 1990.
5. Jenuwein has been awarded numerous honors and awards for his work.
6. He is currently a professor at the Max Planck Institute of Immunobiology and Epigenetics.
7. Jenuwein’s research has contributed to our understanding of gene regulation and disease development.
8. He has published over 200 scientific papers in peer-reviewed journals.
9. Jenuwein serves on several editorial boards for scientific journals.
10. His work has implications for cancer treatment and personalized medicine.